Stay updated with breaking news from True Human. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AUSTIN, Texas, Aug. 08, 2023 -- XBiotech Inc. today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new...
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis TreatmentAUSTIN, Texas, May 22, 2023 -- XBiotech Inc. today reports that the FDA’s Division of Rheumatology... | May 22, 2023
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis TreatmentAUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA's Division of
XBiotech Inc. (NASDAQ: XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin is being developed as a novel treatment to reduce brain injury following ischemic stroke. There are more than 10 ...
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023 -- XBiotech Inc. has enrolled the first subject in a... | April 17, 2023